Natco Pharma urges Indian patent office to deny Gilead’s hepatitis C drug patent in India: Report

11 Apr 2014 Evaluate

Natco Pharma has reportedly urged Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s new hepatitis C drug Sovaldi a patent in India. If happened, this will help the Indian company to launch a cheap generic version of the drug.

Gilead, whose medicine has been hailed by doctors as a breakthrough in treating the liver-destroying disease, has come under fire over its product’s $1,000 per pill price tag in the United States.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

833.85 -6.00 (-0.71%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×